[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiomics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiomics":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,75,114,136,163,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100620111","multimodal-exercise-therapy-for-non-surgical-intervention-of-nonspecific-low-back-pain-100620111",false,"NCT07353372","Multimodal Exercise Therapy for Non-Surgical Intervention of Nonspecific Low Back Pain.","Interventional Study on Paraspinal Muscle Degeneration Leading to Lumbar Degenerative Diseases","METNLBP","Inclusion Criteria:\n\n1. Age ≥ 60 years\n2. Chronic low-back pain for \\> 3 months (no surgical indication)\n3. Planned to receive conservative treatment\n4. Willing to participate and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Specific low-back pain due to infection, tumour, fracture, ankylosing spondylitis, scoliosis, or other structural spinal disorders\n2. Previous lumbar surgery or current surgical indication for lumbar disease 3.Severe cardiopulmonary, hepatic or renal insufficiency that precludes exercise or drug therapy\n\n4.Severe cognitive impairment or psychiatric disorder preventing cooperation 5.Marked exercise limitations or physical disability precluding rehabilitation training 6.Participation in another clinical trial that could interfere with outcomes 7.Known hypersensitivity to any study medication","ALL","60 Years",{"count":20,"type":21},314,"ESTIMATED","INTERVENTIONAL",[24],"NA","This multicenter, assessor-blinded, two-arm parallel randomized controlled trial (N = 314) will compare the efficacy and safety of a 6-week multidimensional exercise program plus usual pharmacological care (experimental arm) versus usual pharmacological care alone (control arm) in adults ≥ 60 years with chronic non-specific low-back pain (LBP) and imaging evidence of paraspinal muscle degeneration. The primary endpoint is change in Oswestry Disability Index (ODI) at 12 months. Secondary endpoints include pain VAS, JOA score, recurrence rate, and patient satisfaction measured repeatedly to 12 months. Advanced MRI radiomics and machine-learning algorithms will be used to build a \"paraspinal muscle imaging-function-prognosis\" prediction model and an open-access web tool for risk stratification. The study will generate a standardized, evidence-based non-operative care pathway for chronic LBP driven by paraspinal muscle degeneration",[27,28,29,30,31],"Paraspinal Muscles","Low Back Pain","Machine Learning","Radiomics","Non-surgical Treatment",[33,34],"Nonsteroidal anti-inflammatory drugs","Multidimensional exercise intervention","NOT_YET_RECRUITING","2026-01-19",{"date":38,"type":39},"2026-01-20","ACTUAL",{"date":41,"type":21},"2026-01-01",{"date":43,"type":21},"2028-09-01",{"name":45,"class":46},"Xuanwu Hospital, Beijing","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":47},"100596830","lymph-node-metastasis-in-early-esophageal-squamous-cell-carcinoma-100596830","NCT07050576","Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma","Deep Learning and Radiomics for Prediction of Lymph Node Metastasis in Early-stage Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Patients with pathologically confirmed early-stage (T1) ESCC\n* Preoperative contrast-enhanced CT data within 2 weeks before surgery\n* Without any treatment before surgical resection\n\nExclusion Criteria:\n\n* Patients who underwent neoadjuvant therapy or endoscopic treatment\n* Insufficient CT imaging or poor CT quality\n* Incomplete pathology results\n* Presence of metastatic disease",{"count":56,"type":21},500,"OBSERVATIONAL","This study aims to develop a predictive model using deep learning and radiomics to assess the likelihood of lymph node metastasis in patients with early-stage esophageal squamous cell carcinoma (ESCC). Lymph node metastasis is a critical factor in determining the treatment approach and prognosis for ESCC patients. By analyzing medical imaging data, we hope to create a non-invasive method that can assist doctors in making more accurate treatment decisions. This research could improve patient outcomes by enabling earlier and more tailored interventions.",[60,61,30],"ESCC","Lymph Node Metastasis",[60,63,64],"Lymph node metastasis","radiomics","RECRUITING","2025-06-26",{"date":68,"type":39},"2025-07-03",{"date":70,"type":39},"2024-05-01",{"date":72,"type":21},"2025-11-30",{"name":74,"class":46},"The First Affiliated Hospital of Anhui Medical University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":83,"conditions":84,"keywords":100,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":47},"100595293","radiomics-to-predict-her2-status-and-t-dxd-efficacy-in-metastatic-breast-cancer-the-radiospher2-study-100595293","NCT07030569","RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study","RADIOSPHER2","Inclusion Criteria:\n\n* Patients with metastatic breast cancer underwent a liver, lung, pleural or bone biopsy in the metastatic setting, performed from 01Jan2005 to 01Jan2024.\n\nExclusion Criteria:\n\n* Not available imaging (CT scan and\u002For PET-FdG scan) in the three months before the biopsy or before the last previous treatment interruption;\n* Unknown HER2 status;\n* Node, soft tissue or other visceral as biopsy site.",{"count":56,"type":21},"RADIOSPHER2 study is a monocentric, retrospective, observational study aiming at identifying a radiomics signature able to predict HER2 expression (0 vs low vs overexpression) and trastuzumab deruxtecan efficacy in metastatic breast cancer patients. The study also encompasses translational analyses and inter-modal correlations in order to provide novel insights about HER2 spatial and temporal heterogeneity, at the macroscopic and microscopic levels.",[85,30,86,87,88,89,90,91,92,93,94,95,96,97,98,99],"Radiomic","Breast Cancer Metastatic","Breast Cancer Stage IV","Breast Carcinoma","Breast Neoplasms","Breast Cancer","Breast Cancer With Bone Metastasis","Breast Cancer With Metastatic Bone Disease","Trastuzumab","HER2","HER2 + Breast Cancer","HER2 Positive Breast Carcinoma","HER2-positive Breast Cancer","Her2\u002FNeu Positive Advanced Solid Tumors","HER2\u002FNeu-positive Breast Cancer",[30,101,102,103,104],"HER2 expression","Trastuzumab Deruxtecan","Pathomics","HER2 heterogeneity","2025-06-12",{"date":107,"type":39},"2025-06-22",{"date":109,"type":39},"2024-02-01",{"date":111,"type":21},"2027-01-01",{"name":113,"class":46},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":120,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":4},"100578003","dixon-mri-imaging-histology-for-predicting-postoperative-infection-in-posterior-lumbar-fusion-for-myasthenia-gravis-100578003","NCT06805643","Dixon MRI Imaging Histology for Predicting Postoperative Infection in Posterior Lumbar Fusion for Myasthenia Gravis","Inclusion Criteria:\n\n* Male and female patients over 18 years of age.\n* Inclusion of patients with sarcopenia is subject to the definition and diagnostic criteria of the European Consensus on Definition and Diagnosis of Sarcopenia.\n* The patient underwent posterior lumbar fusion and had a Dixon MRI scan within 2 weeks prior to surgery.\n* Patients were able to understand the purpose and procedures of the study and were willing to sign an informed consent form.\n* The patient's clinical consultation and follow-up information was complete.\n\nExclusion Criteria:\n\n* The patient has contraindications to MRI, such as implanted metal devices (e.g., pacemakers) or severe claustrophobia.\n* Patients with serious other medical conditions, such as heart disease, kidney disease or liver disease, which may affect their post-operative recovery.\n* Patients have known immune system disorders or are on immunosuppressive therapy, which may affect their risk of infection.\n* The patient has had other spinal surgery within the last 6 months.","18 Years",{"count":122,"type":21},1300,"Sarcopenia is an age-related condition that manifests itself as a persistent decrease in muscle mass and function, which may lead to decreased physical function, increased risk of disease, and reduced quality of life. In surgical patients, sarcopenia has been shown to be associated with increased postoperative complications, prolonged hospitalization, and decreased survival. In patients undergoing lumbar fusion, the presence of sarcopenia may increase the risk of postoperative infection.Lumbar fusion is a common procedure to treat lumbar spine disorders such as lumbar disc herniation, lumbar spondylolisthesis, or lumbar spinal stenosis. However, this procedure is associated with a high rate of complications, especially postoperative infections, which can lead to reoperation, prolonged hospitalization, and even affect patient survival. In recent years, more and more studies have found a significant association between sarcopenia and postoperative infections after lumbar fusion surgery.Imagingomics belongs to a branch of machine learning, which is the process of acquiring images from various imaging devices such as CT, MRI and ultrasound, outlining the region of interest through image segmentation, extracting the features of the image within the region of interest, downscaling the features, and finally building an imagingomics model. MRI Imagingomics, utilizing its rich data information, has shown great potential for application in several medical fields. Among them, the accuracy of Dixon MRI imaging histology in muscle mass and texture assessment makes it particularly important in predicting postoperative infections.Based on this, it is reasonable to believe that Dixon MRI imaging histology can be a powerful tool to help us predict a patient's risk of postoperative infection.",[125,126,30],"Lumbar Vertebrae","Surgical Site Infection","2025-01-28",{"date":129,"type":39},"2025-02-03",{"date":131,"type":21},"2025-02",{"date":133,"type":21},"2026-02-28",{"name":135,"class":46},"The First People's Hospital of Yunnan",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":143,"sex":17,"minAge":120,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":47},"100550859","neurophenotype-predicts-cd-disease-progression-100550859","NCT06452550","Neurophenotype Predicts CD Disease Progression","Multimodal MRI-based Neurophenotype Reflecting Brain-gut Interactions to Predict Intestinal Disease Progression in Patients With Crohn's Disease","Inclusion Criteria:\n\n* (a) CD patients aged 18-45 years; (b) the completion of multimodal brain MRI and administration of psychological questionnaires; (c) MR enterography (MRE), ileocolonoscopy, and blood or faecal samples, collection within one week of brain MRI; (d) a follow-up of at least six months for patients without disease progression; and (e) right-handedness.\n\nExclusion Criteria:\n\n* (a) recent use of antibiotics, probiotics, or prebiotics within three months prior to inclusion; (b) history of neurosurgery, cerebrovascular disease, or brain trauma; (c) use of central nervous system drugs or antidepressants within three months prior to inclusion; (d) identification of brain lesions on MR scan; (e) claustrophobia; or (f) presence of metal implants.",true,"45 Years",{"count":56,"type":21},"The goal of this observational study is aimed to develop a novel multimodal neuroimaging-based model to characterize the neurophenotype of Crohn's Disease patients and assess its ability for predicting disease progression, using multiomics data to interpret the model.\n\nParticipants will be followed-up of at least six months for patients without disease progression to assess the relationship between neurophenotype and intestinal outcomes.",[30,148],"Multi-omics",[150,151,152,153],"Abdominal MRI","Magnetic Resonance Imaging","Crohn's disease","Brain\u002Fgut interaction","2024-06-05",{"date":156,"type":39},"2024-06-11",{"date":158,"type":39},"2021-05-01",{"date":160,"type":21},"2025-06-01",{"name":162,"class":46},"First Affiliated Hospital, Sun Yat-Sen University",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":120,"maxAge":170,"enrollmentInfo":171,"targetDuration":173,"studyType":57,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":47},"100399636","application-of-radiomics-in-breast-cancer-100399636","NCT04483804","Application of Radiomics in Breast Cancer","Application of Radiomics in Correlation Between Ultrasound Characteristics and Pathological Prognostic Factors in Breast Cancer","Inclusion Criteria:\n\nClinical diagnosis of breast cancer\n\nExclusion Criteria:\n\nMissing pathology Missing follow-up results Missing data","80 Years",{"count":172,"type":21},2000,"5 Years","Little is known about the correlation between ultrasound characteristics (conventional, elastography and contrast enhanced ultrasound (CEUS) )and pathological prognostic factors in breast cancer. The aim of this study was to explore the correlation between ultrasound characteristics and pathological prognostic factors using radiomics.",[90,176,177,178,30],"Ultrasound","Elastography","Pathology","2023-03-09",{"date":181,"type":39},"2023-03-10",{"date":183,"type":39},"2018-01-01",{"date":185,"type":21},"2028-12",{"name":187,"class":46},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":17,"minAge":120,"maxAge":170,"enrollmentInfo":194,"targetDuration":173,"studyType":57,"phases":4,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":47},"100467662","stereotactic-radiosurgery-prognosis-assessment-for-spinal-tumors-based-on-radiomics-100467662","NCT05369689","Stereotactic Radiosurgery Prognosis Assessment for Spinal Tumors Based on Radiomics","Inclusion Criteria:\n\nA diagnosis of spinal tumors for which SBRT is appropriate Karnofsky Performance Status \\>60 Life expectancy of at least 3 months No contraindication to undergoing MR imaging Age \\>18 Complete the CT MRI or PET-CT examination before and after treatment Accept stereotactic radiosurgery\n\nExclusion Criteria:\n\nSubjects unable to undergo MRI (includes non-MRI compatible material or devices and severe claustrophobia) Subjects with prior procedural intervention to the involved vertebral body that would result in artifact (kyphoplasty, screw and\u002For rod placement); minimally invasive surgery without instrumentation of the involved vertebral body and instrumentation immediately above or below the index lesion is allowed.\n\nSubjects with spinal cord compression; minimally invasive \"separation\" surgery to first resect the epidural component is allowed Pregnant or breast-feeding women Allergy to standard IV contrast agents used in MRI",{"count":195,"type":21},300,"This study aims to assess multimodal Radiomics-based prediction model for prognostic prediction in spinal tumors.",[198,199,30,200],"Stereotactic Radiosurgery","Spinal Tumor","Prognosis","2022-05-07",{"date":203,"type":39},"2022-05-11",{"date":205,"type":21},"2022-06-01",{"date":207,"type":21},"2027-06-01",{"name":209,"class":46},"Zhuang Hongqing"]